A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).Feng Wen, Yali Shen, Mengni Zhang et al.|Journal of Clinical Oncology|2025Cited by 3
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).Feng Wen, Yali Shen, Min Ren et al.|Journal of Clinical Oncology|2025Cited by 2